Peptide Therapy Foundations: Neuroprotection
Course Details
This course examines the peptides studied for their effects on the brain: the regulatory peptides, neurotrophic preparations, and growth-factor analogs explored for cognition, mood, and neural resilience. It is written for clinicians who want a grounded understanding of how each agent is thought to act, what the evidence shows, and how cautiously each should be read given the state of the research.
The lessons span several mechanistic families. Selank and Semax are short regulatory peptides with effects on neurotransmitter and neurotrophic signaling. Cerebrolysin and Cortexin are neurotrophic preparations studied in neurological recovery. Dihexa, P21, PE22-28, VIP, and IGF-1 LR3 each engage distinct pathways, from growth-factor signaling to synaptogenesis. The maturity of the evidence varies widely across the group, and the lessons say so plainly.
Each lesson follows the same clinical lens: what the agent is, how it works, what the evidence shows, and what a practitioner weighs before applying it. Together they map the neuroprotective peptides as a group so you can reason about any single agent against the others, and against the limits of the data.
SSRP FACULTY
William Seeds, MD
William Seeds, MD
William Seeds, MD
Before establishing the SSRP Institute, Dr. Seeds served as a board-certified orthopedic surgeon and sports medicine specialist for nearly three decades, including Chief of Surgery, Orthopedic Residency Site Director, and Director of The Ohio Bone & Joint Institute for University Hospitals.
His significant contributions to sports medicine have been recognized at the NFL Hall of Fame. He has consulted for athletes across all major sports leagues, including the NFL, NHL, MLB, NBA, and even the performers on “Dancing with the Stars.”
Through his research at the SSRP Institute, Dr. Seeds continues to explore the cellular pathways and mechanisms that positively impact disease and dysfunction in the body as well as optimize physical performance.
VIP
In-ProgressLesson Resources
Overview
Vasoactive intestinal peptide (VIP) is a 28-amino-acid neuropeptide discovered in the 1970s and distributed widely across the central nervous system and peripheral neurons. It is among the most abundant neuropeptides in the brain. This lesson covers how VIP signals through its receptors and where its anti-inflammatory, immunomodulatory, and neuroprotective actions intersect with clinical use.
VIP acts through two G-protein-coupled receptors, VPAC1 and VPAC2. VPAC1 is broadly expressed on immune cells and in the CNS, liver, lung, airway, and gut. VPAC2 is enriched in immune tissue, pancreas, lung, liver, and gut. Both couple to adenylyl cyclase and cyclic AMP.
Mechanism and signaling
The cyclic AMP and PKA cascade is central to VIP’s anti-inflammatory profile. PKA activation inhibits NF-kB, a pro-inflammatory gene transcription factor, by blocking IKK-mediated phosphorylation. VIP also inhibits the p38 MAPK and ERK pathways. Across these routes it can suppress TNF-alpha, interleukin-1 beta, and interleukin-6 while upregulating interleukin-10 and the interleukin-1 receptor antagonist.
On the immune side, VIP suppresses Th1 and Th17 function, induces a Th2 shift, supports regulatory T-cell expansion, and promotes tolerogenic dendritic cells. The speaker frames VIP as an immune modulator rather than a simple booster or suppressor. In neuroprotection, it inhibits microglial activation and the associated release of inducible nitric oxide, interleukin-1 beta, and TNF-alpha, and it promotes neuronal survival via activity-dependent neurotrophic factor.
Clinical evidence and use
The strongest human data comes from a primary pulmonary hypertension study in eight patients using inhaled VIP, which reported improved mean pulmonary artery pressures, cardiac output, and six-minute walk, with systemic blood pressure and heart rate unchanged. Preclinical models support rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. VIP has also been used off label and intranasally in CIRS and mold-illness protocols, typically late in a stepwise Schumacher approach after upstream factors are addressed.
VIP carries a short half-life of roughly one to two minutes from rapid peptidase degradation, which limits systemic use and explains the intranasal and inhalation routes. It is not FDA approved and is prepared as a compounded product requiring refrigeration and protection from light.
Key clinical points
- VIP signals through VPAC1 and VPAC2, driving cyclic AMP and PKA effects that suppress NF-kB and shift the Th17/Treg balance toward tolerance.
- Active malignancy is a contraindication, since VPAC receptors can be overexpressed on some tumors; screen before initiating.
- Watch for lightheadedness and transient hypotension; use caution with antihypertensives, and avoid use in pregnancy given insufficient data.
- Most evidence outside pulmonary hypertension is preclinical or open-label; monitor blood pressure, inflammatory biomarkers, and symptom scores over time.
- The short half-life keeps delivery intranasal or inhaled; nanomedicine and gene-therapy approaches are being studied to address it.
Questions? Our Provider Care Team is here to help.
We'd love to help you determine the best next steps on your Cellular Medicine journey.
Continue your learning journey
VIEW ALLAging-Associated Decline of Phosphatidylcholine Synthesis is a Malleable Trigger of Natural Mitochondrial Aging
Dr. Seeds explores how age-related decline in phosphatidylcholine synthesis may contribute to mitochondrial aging and why that matters in Cellular Medicine. This discussion connects membrane integrity, mitochondrial function, methylation, and metabolic resilience, while highlighting how this pathway may be more modifiable than we once thought.
1. Managing shingles outbreaks in GLP-1 patient through peptides (0:40)
2. Peptide strategies in suspected ALS (15:56)
3. Improving durability in dementia treatment (25:08)
In this bonus episode from the MM15 Virtual Summit, Dr. Seeds addresses an important question around the use of GLP-1s for metabolic balancing in patients who do not need to lose weight. He shares his perspective on what may be considered microdosing, along with the clinical thought process he uses when determining appropriate dosing in these more nuanced cases.
Additional questions from the MM15 Virtual Summit can be found in our accompanying article here: [insert article link]
Access the full MM15 Course here: Mastermind 15 on Aesthetics
The Limits of Alternative Peptide Delivery
Dr. Seeds reviews oral, sublingual, and transdermal peptide delivery, and explains why subcutaneous injection remains the gold standard for most peptides. (Question Link)
A Deeper Look at the RAAS System
Dr. Seeds uses this Rabbit Holes episode to build on Journal Club Episode 87, revisiting the renin-angiotensin-aldosterone system and its broader role in cellular signaling. The discussion focuses on receptor balance, local tissue effects, and the mechanisms linking RAS disruption to inflammation, fibrosis, and mitochondrial stress.(Article Link)
The Renin–Angiotensin–Aldosterone System (RAAS): Beyond Cardiovascular Regulation
Dr. Seeds unpacks how RAS receptor balance drives inflammation, fibrosis, mitochondrial dysfunction, and tissue remodeling, far beyond its classical role in blood pressure regulation. (Article Link)
1. SSRI tapering resistance, anxiety during weaning (0:40)
2. Progressive multifocal dystonia (13:27)
3. Complex type 2 diabetes case in a lean, athletic patient (28:32)